;PMID: 1281274 ;source_file_1009.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..37] = [t:0..37] ;1)sentence:[e:43..139] = [t:43..139] ;2)section:[e:143..190] = [t:143..190] ;3)section:[e:194..246] = [t:194..246] ;4)sentence:[e:250..486] = [t:250..486] ;5)sentence:[e:487..756] = [t:487..756] ;6)sentence:[e:757..949] = [t:757..949] ;7)sentence:[e:950..1316] = [t:950..1316] ;8)sentence:[e:1318..1555] = [t:1318..1555] ;9)sentence:[e:1556..1766] = [t:1556..1766] ;10)sentence:[e:1767..2028] = [t:1767..2028] ;11)sentence:[e:2029..2197] = [t:2029..2197] ;12)sentence:[e:2198..2321] = [t:2198..2321] ;13)section:[e:2325..2369] = [t:2325..2368] ;Sentence Matching Errors ;ERROR_Section end mismatch[e:2325..2369][t:2325..2368] ;Token/POS Errors ;ERROR_Token in entity file but not tree[2368..2369] ] ;section 0 Span:0..37 ;Mutat Res. 1992 Dec 16;284(2):233-41. (SEC (FRAG (NNP:[0..5] Mutat) (NNP:[6..9] Res) (.:[9..10] .) (CD:[11..15] 1992) (NNP:[16..19] Dec) (CC:[20..27] 16;284-LRB-) (CD:[27..28] 2) (-RRB-:[28..29] -RRB-) (CD:[29..33] :233) (::[33..34] -) (CD:[34..36] 41) (.:[36..37] .))) ;sentence 1 Span:43..139 ;Rat pulmonary microsomal cytochrome P-450 enzymes involved in the activation ;of procarcinogens. ;[68..92]:cyp450:"cytochrome P-450 enzymes" ;[124..138]:substance:"procarcinogens" (SENT (NP-HLN (NP (NN:[43..46] Rat) (JJ:[47..56] pulmonary) (JJ:[57..67] microsomal) (NML (NN:[68..78] cytochrome) (NN:[79..84] P-450)) (NNS:[85..92] enzymes)) (VP (VBN:[93..101] involved) (NP (-NONE-:[101..101] *)) (PP-CLR (IN:[102..104] in) (NP (NP (DT:[105..108] the) (NN:[109..119] activation)) (PP (IN:[120..122] of) (NP (NNS:[124..138] procarcinogens)))))) (.:[138..139] .))) ;section 2 Span:143..190 ;Shimada T, Yamazaki H, Mimura M, Guengerich FP. (SEC (FRAG (NNP:[143..150] Shimada) (NNP:[151..152] T) (,:[152..153] ,) (NNP:[154..162] Yamazaki) (NNP:[163..164] H) (,:[164..165] ,) (NNP:[166..172] Mimura) (NNP:[173..174] M) (,:[174..175] ,) (NNP:[176..186] Guengerich) (NNP:[187..189] FP) (.:[189..190] .))) ;section 3 Span:194..246 ;Osaka Prefectural Institute of Public Health, Japan. (SEC (FRAG (NNP:[194..199] Osaka) (NNP:[200..211] Prefectural) (NNP:[212..221] Institute) (IN:[222..224] of) (NNP:[225..231] Public) (NNP:[232..238] Health) (,:[238..239] ,) (NNP:[240..245] Japan) (.:[245..246] .))) ;sentence 4 Span:250..486 ;Rat lung microsomal cytochrome P-450 (P-450) enzymes have been characterized ;with regard to their catalytic specificities towards activation of several ;procarcinogens to genotoxic metabolites in Salmonella typhimurium ;TA1535/pSK1002. ;[270..302]:cyp450:"cytochrome P-450 (P-450) enzymes" ;[404..418]:substance:"procarcinogens" ;[432..443]:substance:"metabolites" (SENT (S (NP-SBJ-1 (NN:[250..253] Rat) (NN:[254..258] lung) (JJ:[259..269] microsomal) (NML (NML (NN:[270..280] cytochrome) (NN:[281..286] P-450)) (NML (-LRB-:[287..288] -LRB-) (CD:[288..293] P-450) (-RRB-:[293..294] -RRB-))) (NNS:[295..302] enzymes)) (VP (VB:[303..307] have) (VP (VBN:[308..312] been) (VP (VBN:[313..326] characterized) (NP-1 (-NONE-:[326..326] *)) (PP (IN:[328..332] with) (NP (NP (NN:[333..339] regard)) (PP (TO:[340..342] to) (NP (NP (PRP$:[343..348] their) (JJ:[349..358] catalytic) (NNS:[359..372] specificities)) (PP (IN:[373..380] towards) (NP (NP (NN:[381..391] activation)) (PP (IN:[392..394] of) (NP (NP (JJ:[395..402] several) (NNS:[404..418] procarcinogens)) (PP (TO:[419..421] to) (NP (JJ:[422..431] genotoxic) (NNS:[432..443] metabolites))))) (PP (IN:[444..446] in) (NP (NNP:[447..457] Salmonella) (NNP:[458..469] typhimurium) (NN:[471..477] TA1535) (SYM:[477..478] /) (NN:[478..485] pSK1002)))))))))))) (.:[485..486] .))) ;sentence 5 Span:487..756 ;We first examined the roles of rat liver microsomal P-450 enzymes in the ;activation of benzo[a]pyrene and its 7,8-diol enantiomers to genotoxic ;products, and found that P-450 1A1 is a major catalyst for the activation of ;these potential procarcinogens in rat livers. ;[539..553]:cyp450:"P-450 enzymes" ;[575..589]:substance:"benzo[a]pyrene" ;[598..618]:substance:"7,8-diol enantiomers" ;[658..667]:cyp450:"P-450 1A1" ;[727..741]:substance:"procarcinogens" (SENT (S (NP-SBJ (PRP:[487..489] We)) (VP (VP (ADVP (RB:[490..495] first)) (VBD:[496..504] examined) (NP (NP (DT:[505..508] the) (NNS:[509..514] roles)) (PP (IN:[515..517] of) (NP (NN:[518..521] rat) (NN:[522..527] liver) (JJ:[528..538] microsomal) (NN:[539..544] P-450) (NNS:[546..553] enzymes)))) (PP (IN:[554..556] in) (NP (NP (DT:[557..560] the) (NN:[561..571] activation)) (PP (IN:[572..574] of) (NP (NP (NN:[575..589] benzo-LSB-a-RSB-pyrene)) (CC:[590..593] and) (NP (PRP$:[594..597] its) (NN:[598..606] 7,8-diol) (NNS:[607..618] enantiomers)))) (PP (TO:[619..621] to) (NP (JJ:[623..632] genotoxic) (NNS:[633..641] products)))))) (,:[641..642] ,) (CC:[643..646] and) (VP (VBD:[647..652] found) (SBAR (IN:[653..657] that) (S (NP-SBJ (NN:[658..663] P-450) (NN:[664..667] 1A1)) (VP (IN:[668..670] is) (NP-PRD (NP (DT:[671..672] a) (JJ:[673..678] major) (NN:[679..687] catalyst)) (PP (IN:[688..691] for) (NP (NP (DT:[692..695] the) (NN:[697..707] activation)) (PP (IN:[708..710] of) (NP (DT:[711..716] these) (JJ:[717..726] potential) (NNS:[727..741] procarcinogens))) (PP-LOC (IN:[742..744] in) (NP (NN:[745..748] rat) (NNS:[749..755] livers))))))))))) (.:[755..756] .))) ;sentence 6 Span:757..949 ;Using lung microsomes isolated from rats treated with various P-450 inducers ;we obtained evidence that at least three P-450 enzymes are involved in the ;activation of several procarcinogens. ;[820..825]:cyp450:"P-450" ;[826..834]:substance:"inducers" ;[877..890]:cyp450:"P-450 enzymes" ;[934..948]:substance:"procarcinogens" (SENT (S (S-MNR (NP-SBJ (-NONE-:[757..757] *)) (VP (VBG:[757..762] Using) (NP (NP (NN:[763..767] lung) (NNS:[769..779] microsomes)) (VP (VBN:[780..788] isolated) (NP (-NONE-:[788..788] *)) (PP (IN:[789..793] from) (NP (NP (NNS:[794..798] rats)) (VP (VBN:[799..806] treated) (NP (-NONE-:[806..806] *)) (PP (IN:[807..811] with) (NP (JJ:[812..819] various) (NN:[820..825] P-450) (NNS:[826..834] inducers)))))))))) (NP-SBJ (PRP:[835..837] we)) (VP (VBD:[838..846] obtained) (NP (NN:[848..856] evidence) (SBAR (IN:[857..861] that) (S (NP-SBJ-1 (QP (IN:[862..864] at) (JJS:[865..870] least) (CD:[871..876] three)) (NN:[877..882] P-450) (NNS:[883..890] enzymes)) (VP (VBP:[891..894] are) (VP (VBN:[895..903] involved) (NP-1 (-NONE-:[903..903] *)) (PP-CLR (IN:[904..906] in) (NP (NP (DT:[907..910] the) (NN:[911..921] activation)) (PP (IN:[922..924] of) (NP (JJ:[926..933] several) (NNS:[934..948] procarcinogens))))))))))) (.:[948..949] .))) ;sentence 7 Span:950..1316 ;Immunoinhibition studies support the view that benzo[a]pyrene and its ;7,8-diol derivatives, other dihydrodiol derivatives of polycyclic aromatic ;hydrocarbons, and 3-amino-1-methyl-5H-pyrido[4,3-b]indole are activated to ;genotoxins mainly by rat P-450 1A1, which is inducible in rat lungs by ;5,6-benzoflavone and the polychlorinated biphenyl mixture Aroclor 1254. ;[998..1012]:substance:"benzo[a]pyrene" ;[1021..1041]:substance:"7,8-diol derivatives" ;[1049..1072]:substance:"dihydrodiol derivatives" ;[1077..1109]:substance:"polycyclic aromatic hydrocarbons" ;[1115..1154]:substance:"3-amino-1-methyl-5H-pyrido[4,3-b]indole" ;[1173..1183]:substance:"genotoxins" ;[1198..1207]:cyp450:"P-450 1A1" ;[1245..1261]:substance:"5,6-benzoflavone" ;[1286..1294]:substance:"biphenyl" ;[1303..1315]:substance:"Aroclor 1254" (SENT (S (NP-SBJ (NN:[950..966] Immunoinhibition) (NNS:[967..974] studies)) (VP (VBP:[975..982] support) (NP (DT:[983..986] the) (NN:[987..991] view) (SBAR (IN:[992..996] that) (S (NP-SBJ-2 (NP (NP (NN:[998..1012] benzo-LSB-a-RSB-pyrene)) (CC:[1013..1016] and) (NP (PRP$:[1017..1020] its) (NN:[1021..1029] 7,8-diol) (NNS:[1030..1041] derivatives))) (,:[1041..1042] ,) (NP (NP (JJ:[1043..1048] other) (NN:[1049..1060] dihydrodiol) (NNS:[1061..1072] derivatives)) (PP (IN:[1073..1075] of) (NP (JJ:[1077..1087] polycyclic) (JJ:[1088..1096] aromatic) (NNS:[1097..1109] hydrocarbons)))) (,:[1109..1110] ,) (CC:[1111..1114] and) (NP (NN:[1115..1154] 3-amino-1-methyl-5H-pyrido-LSB-4,3-b-RSB-indole))) (VP (VBP:[1156..1159] are) (VP (VBN:[1160..1169] activated) (NP-2 (-NONE-:[1169..1169] *)) (PP (TO:[1170..1172] to) (NP (NNS:[1173..1183] genotoxins))) (PP (ADVP (RB:[1184..1190] mainly)) (IN:[1191..1193] by) (NP-LGS (NP (NN:[1194..1197] rat) (NN:[1198..1203] P-450) (NN:[1204..1207] 1A1)) (,:[1207..1208] ,) (SBAR (WHNP-1 (WDT:[1209..1214] which)) (S (NP-SBJ-1 (-NONE-:[1214..1214] *T*)) (VP (VBZ:[1215..1217] is) (ADJP-PRD (JJ:[1218..1227] inducible) (PP-3 (-NONE-:[1227..1227] *ICH*))) (PP-LOC (IN:[1228..1230] in) (NP (NN:[1231..1234] rat) (NNS:[1236..1241] lungs))) (PP-3 (IN:[1242..1244] by) (NP (NP (NN:[1245..1261] 5,6-benzoflavone)) (CC:[1262..1265] and) (NP (NP (DT:[1266..1269] the) (NML (VBN:[1270..1285] polychlorinated) (NN:[1286..1294] biphenyl)) (NN:[1295..1302] mixture)) (NP (NN:[1303..1310] Aroclor) (CD:[1311..1315] 1254)))))))))))))))) (.:[1315..1316] .))) ;sentence 8 Span:1318..1555 ;Activation of 2-amino-3,5-dimethylimidazo[4,5-f]quinoline and ;2-amino-3-methylimidazo[4,5-f]quinoline may be catalyzed by another P-450 ;enzyme because the activities were not induced by treatment with ;5,6-benzoflavone or Aroclor 1254. ;[1332..1375]:substance:"2-amino-3,5-dimethylimidazo[4,5-f]quinoline" ;[1381..1420]:substance:"2-amino-3-methylimidazo[4,5-f]quinoline" ;[1449..1461]:cyp450:"P-450 enzyme" ;[1521..1537]:substance:"5,6-benzoflavone" ;[1542..1554]:substance:"Aroclor 1254" (SENT (S (NP-SBJ-2 (NP (NN:[1318..1328] Activation)) (PP (IN:[1329..1331] of) (NP (NN:[1332..1375] 2-amino-3,5-dimethylimidazo-LSB-4,5-f-RSB-quinoline) (CC:[1376..1379] and) (NN:[1381..1420] 2-amino-3-methylimidazo-LSB-4,5-f-RSB-quinoline)))) (VP (MD:[1421..1424] may) (VP (VB:[1425..1427] be) (VP (VBN:[1428..1437] catalyzed) (NP-2 (-NONE-:[1437..1437] *)) (PP (IN:[1438..1440] by) (NP-LGS (DT:[1441..1448] another) (NN:[1449..1454] P-450) (NN:[1455..1461] enzyme))) (SBAR-PRP (IN:[1463..1470] because) (S (NP-SBJ-1 (DT:[1471..1474] the) (NNS:[1475..1485] activities)) (VP (VBD:[1486..1490] were) (RB:[1491..1494] not) (VP (VBN:[1495..1502] induced) (NP-1 (-NONE-:[1502..1502] *)) (PP (IN:[1503..1505] by) (NP-LGS (NP (NN:[1506..1515] treatment)) (PP (IN:[1516..1520] with) (NP (NP (NN:[1521..1537] 5,6-benzoflavone)) (CC:[1538..1540] or) (NP (NN:[1542..1549] Aroclor) (CD:[1550..1554] 1254))))))))))))) (.:[1554..1555] .))) ;sentence 9 Span:1556..1766 ;The observation that both activities were inhibited by antibodies raised ;against P-450 1A2 and by 7,8-benzoflavone suggests a role for an enzyme of ;P-450 1A family, probably P-450 1A2, in rat lung microsomes. ;[1611..1621]:substance:"antibodies" ;[1638..1647]:cyp450:"P-450 1A2" ;[1655..1671]:substance:"7,8-benzoflavone" ;[1695..1701]:cyp450:"enzyme" ;[1706..1714]:cyp450:"P-450 1A" ;[1732..1741]:cyp450:"P-450 1A2" (SENT (S (NP-SBJ (DT:[1556..1559] The) (NN:[1560..1571] observation) (SBAR (IN:[1572..1576] that) (S (NP-SBJ-1 (DT:[1577..1581] both) (NNS:[1582..1592] activities)) (VP (VBD:[1593..1597] were) (VP (VBN:[1598..1607] inhibited) (NP-1 (-NONE-:[1607..1607] *)) (PP (PP (IN:[1608..1610] by) (NP-LGS (NP (NNS:[1611..1621] antibodies)) (VP (VBN:[1623..1629] raised) (NP (-NONE-:[1629..1629] *)) (PP (IN:[1630..1637] against) (NP (NN:[1638..1643] P-450) (NN:[1644..1647] 1A2)))))) (CC:[1648..1651] and) (PP (IN:[1652..1654] by) (NP-LGS (NN:[1655..1671] 7,8-benzoflavone))))))))) (VP (VBZ:[1672..1680] suggests) (NP (NP (DT:[1681..1682] a) (NN:[1683..1687] role)) (PP (IN:[1688..1691] for) (NP (NP (NP (DT:[1692..1694] an) (NN:[1695..1701] enzyme)) (PP (IN:[1703..1705] of) (NP (NML (NN:[1706..1711] P-450) (NN:[1712..1714] 1A)) (NN:[1715..1721] family)))) (,:[1721..1722] ,) (NP (ADVP (RB:[1723..1731] probably)) (NN:[1732..1737] P-450) (NN:[1738..1741] 1A2))))) (,:[1741..1742] ,) (PP-LOC (IN:[1743..1745] in) (NP (NN:[1746..1749] rat) (NN:[1750..1754] lung) (NNS:[1755..1765] microsomes)))) (.:[1765..1766] .))) ;sentence 10 Span:1767..2028 ;The activation of aflatoxin B1 and sterigmatocystin appears to be catalyzed ;by other P-450 enzyme(s) rather than the P-450 1A family as judged by the ;different responses of activities to the P-450 inducers and the specific ;antibodies in rat lung microsomes. ;[1786..1798]:substance:"aflatoxin B1" ;[1803..1819]:substance:"sterigmatocystin" ;[1853..1869]:cyp450:"P-450 enzyme(s)" ;[1886..1894]:cyp450:"P-450 1A" ;[1961..1966]:cyp450:"P-450" ;[1967..1975]:substance:"inducers" ;[1993..2003]:substance:"antibodies" (SENT (S (NP-SBJ-1 (NP (DT:[1767..1770] The) (NN:[1771..1781] activation)) (PP (IN:[1783..1785] of) (NP (NP (NN:[1786..1795] aflatoxin) (NN:[1796..1798] B1)) (CC:[1799..1802] and) (NP (NN:[1803..1819] sterigmatocystin))))) (VP (VBZ:[1820..1827] appears) (S (NP-SBJ-1 (-NONE-:[1827..1827] *)) (VP (TO:[1828..1830] to) (VP (VB:[1831..1833] be) (VP (VBN:[1834..1843] catalyzed) (NP-1 (-NONE-:[1843..1843] *)) (PP (IN:[1844..1846] by) (NP-LGS (NP (JJ:[1847..1852] other) (NN:[1853..1858] P-450) (NNS:[1860..1869] enzyme-LRB-s-RRB-)) (PP (RB:[1870..1876] rather) (IN:[1877..1881] than) (NP (DT:[1882..1885] the) (NN:[1886..1891] P-450) (NN:[1892..1894] 1A) (NN:[1895..1901] family))))) (SBAR-ADV (IN:[1902..1904] as) (S (NP-SBJ-2 (-NONE-:[1904..1904] *)) (VP (VBN:[1905..1911] judged) (NP-2 (-NONE-:[1911..1911] *)) (PP-MNR (IN:[1912..1914] by) (NP (NP (DT:[1915..1918] the) (JJ:[1919..1928] different) (NNS:[1929..1938] responses)) (PP (IN:[1940..1942] of) (NP (NNS:[1943..1953] activities))) (PP (TO:[1954..1956] to) (NP (NP (NP (DT:[1957..1960] the) (NN:[1961..1966] P-450) (NNS:[1967..1975] inducers)) (CC:[1976..1979] and) (NP (DT:[1980..1983] the) (JJ:[1984..1992] specific) (NN:[1993..2003] antibodies))) (PP-LOC (IN:[2004..2006] in) (NP (NN:[2007..2010] rat) (NN:[2011..2015] lung) (NNS:[2017..2027] microsomes))))))))))))))) (.:[2027..2028] .))) ;sentence 11 Span:2029..2197 ;Interestingly, lung microsomal activation of several procarcinogens was ;found to be suppressed in rats treated with isosafrole and pregnenolone 16 ;alpha-carbonitrile. ;[2082..2096]:substance:"procarcinogens" ;[2146..2156]:substance:"isosafrole" ;[2161..2196]:substance:"pregnenolone 16 alpha-carbonitrile" (SENT (S (ADVP (RB:[2029..2042] Interestingly)) (,:[2042..2043] ,) (NP-SBJ-1 (NP (NN:[2044..2048] lung) (JJ:[2049..2059] microsomal) (NN:[2060..2070] activation)) (PP (IN:[2071..2073] of) (NP (JJ:[2074..2081] several) (NNS:[2082..2096] procarcinogens)))) (VP (VBD:[2098..2101] was) (VP (VBN:[2102..2107] found) (S (NP-SBJ-1 (-NONE-:[2107..2107] *)) (VP (TO:[2108..2110] to) (VP (VB:[2111..2113] be) (VP (VBN:[2114..2124] suppressed) (NP-1 (-NONE-:[2124..2124] *)) (PP-LOC (IN:[2125..2127] in) (NP (NP (NNS:[2128..2132] rats)) (VP (VBN:[2133..2140] treated) (NP (-NONE-:[2140..2140] *)) (PP-MNR (IN:[2141..2145] with) (NP (NP (NN:[2146..2156] isosafrole)) (CC:[2157..2160] and) (NP (NN:[2161..2173] pregnenolone) (CD:[2174..2176] 16) (NN:[2178..2196] alpha-carbonitrile))))))))))))) (.:[2196..2197] .))) ;sentence 12 Span:2198..2321 ;Thus, the results support the roles of different P-450 enzymes in the ;activation of procarcinogens in rat lung microsomes. ;[2247..2261]:cyp450:"P-450 enzymes" ;[2283..2297]:substance:"procarcinogens" (SENT (S (ADVP (RB:[2198..2202] Thus)) (,:[2202..2203] ,) (NP-SBJ (DT:[2204..2207] the) (NNS:[2208..2215] results)) (VP (IN:[2216..2223] support) (NP (NP (DT:[2224..2227] the) (NNS:[2228..2233] roles)) (PP (IN:[2234..2236] of) (NP (JJ:[2237..2246] different) (NN:[2247..2252] P-450) (NNS:[2254..2261] enzymes))) (PP (IN:[2262..2264] in) (NP (NP (DT:[2265..2268] the) (NN:[2269..2279] activation)) (PP (IN:[2280..2282] of) (NP (NNS:[2283..2297] procarcinogens))) (PP-LOC (IN:[2298..2300] in) (NP (NN:[2301..2304] rat) (NN:[2305..2309] lung) (NNS:[2310..2320] microsomes))))))) (.:[2320..2321] .))) ;section 13 Span:2325..2368 ;PMID: 1281274 [PubMed - indexed for MEDLINE (SEC (FRAG (NNP:[2325..2329] PMID) (::[2329..2330] :) (CD:[2331..2338] 1281274) (-LRB-:[2339..2340] -LSB-) (NNP:[2340..2346] PubMed) (::[2347..2348] -) (VBN:[2349..2356] indexed) (IN:[2357..2360] for) (NNP:[2361..2368] MEDLINE))) ;ERROR_Orphan Text from EOF Tree File[2368..EOF] ] (ORPH -RSB-)